Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection
Neuropeptide Y (NPY) and related peptides have been proposed as promising biomarkers for the diagnosis of prostate cancer by previous immunoassays and immunohistochemical studies. In this study, we evaluated the additional value of NPY and related peptides compared with prostate-specific antigen (PS...
Главные авторы: | Maurer, J, Eugster, PJ, Collins, K, Vocat, C, Oke, J, Nicholson, B, Rakauskas, A, Grouzmann, E, Valerio, M |
---|---|
Формат: | Journal article |
Язык: | English |
Опубликовано: |
Elsevier
2024
|
Схожие документы
-
Neuropeptide Y and Derivates Are Not Ready for Prime Time in Prostate Cancer Early Detection
по: Jonathan Maurer, и др.
Опубликовано: (2024-08-01) -
Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?
по: Alexander Meisel
Опубликовано: (2019-12-01) -
Saxagliptin: A potential doping agent? A randomized, double‐blinded, placebo‐controlled, and crossover pilot study in young active men
по: Nicolas Bourdillon, и др.
Опубликовано: (2022-12-01) -
Biomarkers in early-stage colorectal cancer: ready for prime time?
по: Church, D, и др.
Опубликовано: (2012) -
REBOA: is it ready for prime time?
по: Jay Doucet, и др.